00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:47 , Jun 24, 2019 |  BC Extra  |  Company News

June 24 Company Quick Takes: Terns gains Chinese rights to elafibranor; plus venetoclax, Zejula and more

Terns gets Chinese rights to Genfit's liver disease candidate  Terns Pharmaceuticals Inc. (San Mateo, Calif.) licensed rights to elafibranor (GFT505) from Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) to treat non-alcoholic steatohepatitis and primary biliary cholangitis in China,...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
12:19 , Apr 4, 2019 |  BC Extra  |  Financial News

Liver disease play NGM raises $106.7M in IPO

Shares in NGM slipped $1.30 to $14.70 on Thursday after the company raised $106.7 million in an IPO that priced at the top of the company's proposed range. NGM Biopharmaceuticals Inc. (NASDAQ:NGM) sold 6.7 million...
13:47 , Mar 27, 2019 |  BC Extra  |  Financial News

NASH company Genfit gains dual listing via NASDAQ offering

Liver disease company Genfit gained $1.85 to $22.17 on Wednesday after the company raised a combined $135.1 million via a NASDAQ offering and concurrent private placement. In the NASDAQ offering, Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) raised...
20:09 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
05:48 , Feb 28, 2019 |  BC Extra  |  Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
16:57 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Intercept's NASH therapy heads for submissions after meeting Phase III endpoint

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) intends to submit regulatory applications next half for obeticholic acid (OCA) after new data showed the compound met one of two primary endpoints in the Phase III REGENERATE trial to treat...
17:52 , Feb 19, 2019 |  BC Extra  |  Clinical News

Intercept's NASH therapy heads for submissions after meeting Phase III endpoint

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) intends to submit regulatory applications next half for obeticholic acid (OCA) after new data showed the compound met one of two primary endpoints in the Phase III REGENERATE study to treat...